|Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.|
|Jump to Full Text|
|PMID: 20122250 Owner: NLM Status: MEDLINE|
|BACKGROUND: Castleman disease (CD) is a rare benign disorder characterised by hyperplasia of lymphoid tissue that may develop at a single site or throughout the body. The etiology of this disorder is unclear, although the histopathological presentation can be differentiated into a hyaline vascular variant, a plasma cell variant and a mixed variant. Clinically, it has been recorded that 3 manifestations of CD are characterized: a localized unicentric type, a generalized multicentric type and a mixed form. Surgery remains the main treatment for resectable unicentric CD, since removal of the large node is possible without further complications. No consensus has been reached concerning the most adequate treatment for irresectable unicentric CD. METHODS: Case report of a 67 year old woman. RESULTS: This report, describes the case of a 67-year-old woman with unicentric Castleman disease located in the right lower abdomen. The patient had symptoms of fatigue, dyspnoea and pain in the right lower abdomen. Computed tomography (CT)- examination revealed a tumour, which had grown to form a close relationship with the common iliac vessels and the sacral bone. A Laparotomy procedure revealed that the tumour was an irresectable mass. Neo-adjuvant radiotherapy (40 Gy) was administered in order to downsize the tumour. Six weeks later a new CT-scan revealed a major reduction of the tumour, which enabled a successful radical resection of the tumour to be performed. Histopathological analysis of the tumour showed the hyaline vascular type of CD. CONCLUSIONS: Neo-adjuvant radiotherapy should be considered in case of an irresectable unicentric CD.|
|Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen|
|Type: Case Reports; Journal Article; Randomized Controlled Trial; Review Date: 2010-02-02|
|Title: Radiation oncology (London, England) Volume: 5 ISSN: 1748-717X ISO Abbreviation: Radiat Oncol Publication Date: 2010|
|Created Date: 2010-02-24 Completed Date: 2010-05-19 Revised Date: 2010-09-28|
Medline Journal Info:
|Nlm Unique ID: 101265111 Medline TA: Radiat Oncol Country: England|
|Languages: eng Pagination: 7 Citation Subset: IM|
|Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.|
|APA/MLA Format Download EndNote Download BibTex|
Anemia / complications
Exophthalmos / complications
Giant Lymph Node Hyperplasia / complications, radiotherapy*, surgery
Hyperthyroidism / complications
Tomography, X-Ray Computed
Journal ID (nlm-ta): Radiat Oncol
Publisher: BioMed Central
Copyright ?2010 de Vries et al; licensee BioMed Central Ltd.
Received Day: 26 Month: 9 Year: 2009
Accepted Day: 2 Month: 2 Year: 2010
collection publication date: Year: 2010
Electronic publication date: Day: 2 Month: 2 Year: 2010
Volume: 5First Page: 7 Last Page: 7
Publisher Id: 1748-717X-5-7
PubMed Id: 20122250
|Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature|
|Iris AC de Vries1||Email: email@example.com|
|Marjolein MS van Acht1||Email: firstname.lastname@example.org|
|Thomas BJ Demeyere2||Email: email@example.com|
|Marnix LM Lybeert3||Email: firstname.lastname@example.org|
|Jean-Paul de Zoete1||Email: email@example.com|
|Grard AP Nieuwenhuijzen1||Email: firstname.lastname@example.org|
1Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands
2Department of Pathology, Catharina Hospital, Eindhoven, The Netherlands
3Department of Radiotherapy, Catharina Hospital, Eindhoven, The Netherlands
In 1954, Benjamin Castleman described an unusual benign disorder that was characterized by hyperplasia of lymphoid tissue . A couple of years later, Castleman et al  published more cases with benign massive growth of lymph nodes that is commonly referred to as Castleman's disease (CD). Flendrig et al  categorised two main types and one mixed variant of CD. Keller et al  defined these histopathological different patterns.
The first being a hyaline vascular type (HV), characterized by lymphoid follicular hyperplasia with involuted germinal centres, which are partly or totally replaced by deposit of hyaline material and transfixed by a radially penetrating vessel, characterized as a 'lolly pop' structure. The second variant was defined as the plasma cell type (PC) with a follicular hyperplasia of hyperplastic, large germinal centres in which the interfollicular areas were occupied by large sheets of plasma cells.
Clinically a broad spectrum of manifestations of CD are described, ranging from an asymptomatic localized lymphadenopathy to a severe symptomatic multifocal or generalized lymphadenopathy . A commonly used system to classify the heterogeneity of CD was proposed by McCarty et al in 1995 . This made a distinction between the unicentric and the multicentric forms of disease. This classification correlates quite well with the histopathologically variants. As the HV type is mostly unicentric and the PC type and the mixed variant seem to be mostly multicentric [7,8].
CD has to be treated because of its progressive course associated with local involvement of surrounding structures or because of the systemic effects associated with the multicentric form such as fever, weight loss, excessive sweating, hemolytic anaemia, splenomegaly, oedema and neuropathy.
CD can also be associated with HIV infection, POEMS syndrome, amyloidosis, renal insufficiency and increased risk of lymphoma [5,9-11], these conditions necessitate diagnostic and therapeutic intervention.
Surgery is considered to be the most adequate therapy for unicentric resectable cases of CD, as it seems to be curative in almost all of the cases [4,6,12-20]. Radiotherapy has also been described as a definitive treatment, however with a variable response rate [4,9,10,21-30].
No consensus has been reached concerning the most adequate treatment for irresectable CD. To our knowledge, neo-adjuvant radiotherapy to downsize primary irresectable CD in order to achieve a radical surgical resection has not been described yet. This paper reviews the associated literature concerning the treatment of CD and describes a case history of an irresectable unicentric localisation of CD which was treated with neo-adjuvant radiotherapy and subsequent radical resection.
A 67-year-old woman with a history of hyperthyroidism, proptosis and anaemia was referred to the internal medicine department with complaints of weight loss, fatigue, dyspnea and pain in the right lower abdomen. Physical examination revealed a painful palpable mass in the right lower quadrant of the abdomen.
Ultrasonography of the abdomen showed a multicystic, solid structure in the right lower abdomen. Subsequent Computed Tomography (CT) imaging of the abdomen showed right ventrally of the body of the first sacral vertebrum a partly solid, partly cystic tumour of 71 ? 51 mm with oedematous infiltration of the surrounding adipose tissue and a close relationship with the common iliac artery and vein (figure 1A). Since the radiological aspect was initially presumed to be indicative of ovarian cancer, the patient was referred for gynaecological examination. Transvaginal ultrasound showed a polycystic structure on the right side. CA125 was normal. The patient underwent a staging laparotomy by the gynaecologist, revealing a normal uterus, normal ovaries and a fixed retroperitoneal tumour located to the right side of the aortic bifurcation. A surgeon oncologist was consulted, and because of the fixation and close relationship of the tumour to the iliac vessels and sacral bone, the tumour was regarded as primary irresectable and only an incisional biopsy was performed to obtain material for histological examination. Histopathology from the specimen revealed lymphoid hyperplasia, atrophic germinal centers and radialy penetrating vessels (lollypop phenomenon) as seen in the HV variant of CD, (figure 2). A subsequent positron emission tomogram (PET)-scan revealed no signs of disseminated disease. There were no laboratory abnormalities and the HIV test turned out to be negative. Since the tumour was regarded irresectable, neo-adjuvant radiotherapy was proposed in order to downsize the tumour to achieve a radical surgical excision. Neo-adjuvant radiotherapy was delivered by means of a 4-field technique to a dose of 40 Gy in 20 fractions of 2 Gy. Six weeks later a CT-scan, revealed a major downsizing with a maximal diameter of the tumour of 47 mm, which was initially 72 mm (figure 1B). A subsequent laparotomy revealed a mobile tumour and a radical resection was performed without complications. An intraoperative boost (IORT) of 10 Gy was applied to the presacral resection surface. The patient recovered without complications and final histology showed a cystic residual localisation of CD of the HV type with free resection margins. At present, two years and 3 months after resection of the tumour no signs of recurrence have been detected.
This report documents a unique case of a primary irresectable case of the HV unicentric type of CD which was treated with neoadjuvant radiotherapy and subsequent successful radical resection. To our knowledge, there is no report in the literature describing neoadjuvant radiotherapy as part of the treatment of unicentric CD.
The etiology of Castleman's Disease is unknown. However, CD is associated with other disorders such as HIV infection, POEMS syndrome, amyloidosis, renal insufficiency and increased risk of lymphoma [5,9-11]. Therefore specific systemic therapy related to the associated disorder is indicated. There is no consensus yet concerning the most adequate treatment for CD. Surgery is considered to be the most adequate therapy for unicentric cases of CD as it seems to be curative in most of the cases [4,6,12-20]. Various strategies have been described in case of irresectable unicentric CD ranging from primary radiotherapy, incomplete resection  and chemotherapy .
Primary radiotherapy has been described in numerous case reports and small case series as one of the strategies for the treatment of both unicentric and multicentric forms of CD. Keller et al  however described that in 4 cases primary radiotherapy had only a minimal effect and concluded that radiotherapy alone was not effective. However, several cases have been reported with significant responses to primary radiotherapy, for the unicentric as well as for the multicentric form of CD [9,10,21-23,25-30,32,33]. Table 1, presents an overview of all studies that have evaluated the use of primary radiotherapy in CD, both for unicentric and multicentric disease, with doses ranging from 12 to 50 Gy [4,8-10,22-30,32,34,35]. Responses to primary radiotherapy for the treatment of both forms of CD ranged from no response to a complete response. Nevertheless, 88% of all CD patients treated with radiotherapy showed a response, of which 43,8% showed a complete response.
With respect to the dose of radiotherapy, no correlation can be observed between dose and response. Most patients were treated with a dose between 40 and 50 Gy, however patients with a complete response received a dose between 12 Gy and 50 Gy.
The evidence in the current literature reveals that radical surgery results in excellent rates of cure [4,6,12-19]. Also the literature reports excellent response rates with primary radiotherapy (table 1). Therefore it was concluded that, in case of an irresectable presentation of unicentric CD, surgery after neoadjuvant radiotherapy was a possible strategy. This case illustrates that this hypothesis was successful and should be considered as a strategy in case of irresectable unicentric disease. The question remains which policy should be followed in case of a complete radiologic response. Although merely speculative, a wait and see policy with regular radiological follow-up could be a reasonable strategy in case of no systemic symptoms, since most reports describe unicentric CD as a slowly progressive disease, which does not metastasize. In the case where a recurrence of residual disease is found, a resection in an early stage could still be performed. In that case we propose a frequent follow up, using CT scanning every six months, since unicentric CD is a slowly progressive disease. In case of a partial response to primary radiotherapy, we suggest that surgical resection is strongly recommended, since radical surgery can potentially cure unicentric CD.
Surgery was performed six weeks after the last radiotherapy dose. The rationale for this interval is based on the experience gained from treatments with other neoadjuvant strategies in solid tumours .
Different types of therapy have been described for the treatment of patients with multicentric CD. However the treatment strategy for this variant of CD is not within the scope of this article. Nevertheless, the literature reveals that primary radiotherapy can also achieve a remission of symptoms [10,24,26,28,30,32] and given the fact that multicentric CD, more often then unicentric CD, causes generalised symptoms, radiotherapy could also be used as a symptomatic treatment.
The rationale of our additional intra-operative radiotherapy (IORT) boost was based on the close relationship with the sacral bone and iliac vessels and was analogous to our management of other locally advanced solid tumours like rectal cancer and soft tissue sarcomas [37-40].
In this case report it is demonstrated that neo-adjuvant radiotherapy in case of locally advanced irresectable unicentric CD facilitates a radical resection. Therefore, analogous with the treatment of other locally advanced solid tumours, neo-adjuvant radiotherapy with a dose of 40-50 Gy and a subsequent resection 6 weeks later should be considered if an irresectable unicentric variant of CD is encountered.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
IAC, MMS, GAP have made substantial contributions to conception and design, and acquisition of data and analysis and interpretation of data. IAC, MMS, T, MLM, JP, GAP have been involved in drafting the manuscript or revising it critically for important intellectual content. All authors read and approved the final manuscript.
|Castleman B,Towne VW,Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. CabotN Engl J MedYear: 19542511039640013194083|
|Castleman B,Iverson L,Menendez VP,Localized mediastinal lymphnode hyperplasia resembling thymomaCancerYear: 19569482283010.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-413356266|
|Flendrig J,Benign giant lymphoma: clinicopathologic correlation studyYear: 1970Chicago: Yearbook Medical Publishers296299|
|Keller AR,Hochholzer L,Castleman B,Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locationsCancerYear: 197229367068310.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#4551306|
|Casper C,The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient careBr J HaematolYear: 2005129131710.1111/j.1365-2141.2004.05311.x15801951|
|McCarty MJ,Vukelja SJ,Banks PM,Weiss RB,Angiofollicular lymph node hyperplasia (Castleman's disease)Cancer Treat RevYear: 199521429131010.1016/0305-7372(95)90034-97585657|
|Dispenzieri A,Gertz MA,Treatment of Castleman's diseaseCurr Treat Options OncolYear: 20056325526610.1007/s11864-005-0008-z15869736|
|Gaba AR,Stein RS,Sweet DL,Variakojis D,Multicentric giant lymph node hyperplasiaAm J Clin PatholYear: 19786918690619617|
|Bowne WB,Lewis JJ,Filippa DA,Niesvizky R,Brooks AD,Burt ME,Brennan MF,The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literatureCancerYear: 199985370671710.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-710091744|
|Chronowski GM,Ha CS,Wilder RB,Cabanillas F,Manning J,Cox JD,Treatment of unicentric and multicentric Castleman disease and the role of radiotherapyCancerYear: 200192367067610.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q11505414|
|Herrada J,Cabanillas F,Rice L,Manning J,Pugh W,The clinical behavior of localized and multicentric Castleman diseaseAnn Intern MedYear: 199812886576629537940|
|Frizzera G,Castleman's disease: more questions than answersHum PatholYear: 198516320220510.1016/S0046-8177(85)80002-23871724|
|Frizzera G,Castleman's disease and related disordersSemin Diagn PatholYear: 1988543463642464187|
|Humphreys SR,Holley KE,Smith LH,McIlrath DC,Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephroitc syndromeMayo Clin ProcYear: 19755063173211127997|
|LeVan TA,Clifford S,Staren ED,Castleman's tumor masquerading as a pancreatic neoplasmSurgeryYear: 198910658848872683174|
|Menke DM,Camoriano JK,Banks PM,Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysisMod PatholYear: 1992555255301285353|
|Seco JL,Velasco F,Manuel JS,Serrano SR,Tomas L,Velasco A,Retroperitoneal Castleman's diseaseSurgeryYear: 199211258508551440235|
|Shahidi H,Myers JL,Kvale PA,Castleman's diseaseMayo Clin ProcYear: 1995701096997710.4065/70.10.9697564550|
|Shroff VJ,Gilchrist BF,DeLuca FG,McCombs HL,Wesselhoeft CW,Castleman's disease presenting as a pediatric surgical problemJ Pediatr SurgYear: 199530574574710.1016/0022-3468(95)90707-67623245|
|Martino G,Cariati S,Tintisona O,Veneroso S,De Villa F,Vergine M,Monti M,Atypical lymphoproliferative disorders: Castleman's disease. Case report and review of the literatureTumoriYear: 200490335235515315321|
|Gittinger JW Jr,Ocular involvement in Castleman's disease. Response to radiotherapyOphthalmologyYear: 19899611164616492616150|
|Latz D,Mende U,Schraube P,Rieden K,[The radiotherapy of Castleman's lymphoma]Strahlenther OnkolYear: 199216852972991598666|
|Marti S,Pahissa A,Guardia J,Moragas A,Bacardi R,Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapyCancerYear: 198351580881010.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-56821846|
|Massey GV,Kornstein MJ,Wahl D,Huang XL,McCrady CW,Carchman RA,Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findingsCancerYear: 19916861365137210.1002/1097-0142(19910915)68:6<1365::AID-CNCR2820680630>3.0.CO;2-Q1873789|
|Neuhof D,Debus J,Outcome and late complications of radiotherapy in patients with unicentric Castleman diseaseActa OncolYear: 20064581126113110.1080/0284186060081270117118850|
|Nordstrom DG,Tewfik HH,Latourette HB,Giant lymph node hyperplasia: a review of literature and report of two cases of plasma cell variant responding to radiation therapyInt J Radiat Oncol Biol PhysYear: 1978411-1210451048102620|
|Sethi T,Joshi K,Sharma SC,Gupta BD,Radiation therapy in the management of giant lymph node hyperplasiaBr J RadiolYear: 19906375264865010.1259/0007-1285-63-752-6482400884|
|Stokes SH,Griffith RC,Thomas PR,Angiofollicular lymph node hyperplasia (Castleman's disease) associated with vertebral destructionCancerYear: 198556487687910.1002/1097-0142(19850815)56:4<876::AID-CNCR2820560429>3.0.CO;2-C4016679|
|Veldhuis GJ,Leest AH van der,de Wolf JT,de Vries EG,Vellenga E,A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspectsAnn HematolYear: 1996731475010.1007/s0027700502018695726|
|Weisenburger DD,DeGowin RL,Gibson P,Armitage JO,Remission of giant lymph node hyperplasia with anemia after radiotherapyCancerYear: 197944245746210.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4476562|
|Dispenzieri A,Castleman diseaseCancer Treat ResYear: 200814229333018283792|
|Nordstrom DG,Tewfik HH,Latourette HB,Plasma cell giant lymph node hyperplasia responding to radiation therapyAJR Am J RoentgenolYear: 19781301169171413407|
|Yoshida K,Suzuki T,Sakata T,Kawai N,Matsuda A,Kayano H,Hirashima K,Matsutani M,Bessho M,Successful treatment of multicentric Castleman's disease with intracranial and retroperitoneal tumorsIntern MedYear: 200140997697710.2169/internalmedicine.40.97611579970|
|Emson HE,Extrathoracic angiofollicular lymphoid hyperplasia with coincidental myasthenia gravisCancerYear: 197331124124510.1002/1097-0142(197301)31:1<241::AID-CNCR2820310132>3.0.CO;2-T4683040|
|Fitzpatrick PJ,Brown TC,Angiofollicular lymph node hyperplasiaCan Med Assoc JYear: 19689925125912625700853|
|Lim SB,Choi HS,Jeong SY,Kim DY,Jung KH,Hong YS,Chang HJ,Park JG,Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancersAnn SurgYear: 2008248224325110.1097/SLA.0b013e31817fc2a018650634|
|Sadahiro S,Suzuki T,Ishikawa K,Yasuda S,Tajima T,Makuuchi H,Murayama C,Ohizumi Y,Intraoperative radiation therapy for curatively resected rectal cancerDis Colon RectumYear: 200144111689169510.1007/BF0223439111711743|
|Stitzenberg KB,Klauber-Demore N,Chang XS,Calvo BF,Ollila DW,Goyal LK,Meyers MO,Kim HJ,Tepper JE,Sartor CI,In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancerAnn Surg OncolYear: 20071441515151610.1245/s10434-006-9152-317235715|
|Willett CG,Suit HD,Tepper JE,Mankin HJ,Convery K,Rosenberg AL,Wood WC,Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcomaCancerYear: 199168227828310.1002/1097-0142(19910715)68:2<278::AID-CNCR2820680211>3.0.CO;2-C1906369|
|Willett CG,Czito BG,Tyler DS,Intraoperative radiation therapyJ Clin OncolYear: 200725897197710.1200/JCO.2006.10.025517350946|
Summary of reports describing patients with CD treated with primary radiotherapy
|Reference||Number of patients
(n = 32)
|Fitzpatrick et al. (1968)||1||-||Unicentric||4500||PR|
|Keller et al. (1972)||4||HV||Unicentric||1800-4300||PR|
|Emson et al. (1973)||1||-||-||3500||PR|
|Nordstrom et al. (1978)||1||PC||Unicentric||2700||PR|
|Nordstrom et al. (1978)||1||PC||Unicentric||2700||PR|
|Gaba et al. (1978)||1||HV||Multicentric||4500||NR|
|Weisenburger et al. (1979)||1||PC||Unicentric||2700||PR|
|Marti et al. (1983)||1||M||Multicentric||1200||CR|
|Stokes et al. (1985)||1||PC||Unicentric||3939||PR|
|Sethi et al (1990)||1||HV||Unicentric||4500||CR|
|Massey et al. (1991)||1||M||Unicentric||3040||PR|
|Latz et al. (1992)||1||HV||Unicentric||4000||CR|
|Veldhuis et al. (1996)||1||PC||Unicentric||4000||CR|
|Bowne et al. (1999)||1||HV||Unicentric||4500||NR|
|Chronowski et al.(2001)||4||HV||Unicentric||4000||CR|
|Neuhof and Debus (2006)||1||HV||Unicentric||4000-5000||NR|
|Neuhof and Debus (2006)||1||M||Unicentric||4000-5000||NR|
|All Reports||32||CR: 14/32:43,8%
PC (plasma cell type); HV (hyaline vascular type); M (mixed HV and PC type); PR (partial response);
CR (complete response); NR (non response);
Previous Document: Bayesian salamanders: analysing the demography of an underground population of the European plethodo...
Next Document: A nonsense mutation in the beta-carotene oxygenase 2 (BCO2) gene is tightly associated with accumula...